Baclofen modulates cardiovascular responses to appetitive cues in treatment‐seeking alcohol use disorder individuals

2020 ◽  
Vol 35 (2) ◽  
Author(s):  
Warren B. Logge ◽  
Andrew J. Baillie ◽  
Paul S. Haber ◽  
Kirsten C. Morley
Keyword(s):  
Alcohol Use ◽  
Alcohol Use Disorder ◽  
Cardiovascular Responses ◽  
Treatment Seeking ◽  
Appetitive Cues

DSM-5 alcohol use disorder features among treatment-seeking older adults

2018 ◽  
Vol 64 (4) ◽  
pp. 185-196 ◽  
Author(s):  
Silke Behrendt ◽  
Barbara Braun ◽  
Randi Bilberg ◽  
Gerhard Bühringer ◽  
Michael Bogenschutz ◽  
...  
Keyword(s):  
Older Adults ◽  
Alcohol Use ◽  
Alcohol Use Disorder ◽  
The Elderly ◽  
Treatment Seeking ◽  
Controlled Clinical Trial ◽  
Dsm 5 ◽  
Wide Range ◽  
And Gender ◽  
International Multicenter

Abstract. Background: The number of older adults with alcohol use disorder (AUD) is expected to rise. Adapted treatments for this group are lacking and information on AUD features in treatment seeking older adults is scarce. The international multicenter randomized-controlled clinical trial “ELDERLY-Study” with few exclusion criteria was conducted to investigate two outpatient AUD-treatments for adults aged 60+ with DSM-5 AUD. Aims: To add to 1) basic methodological information on the ELDERLY-Study by providing information on AUD features in ELDERLY-participants taking into account country and gender, and 2) knowledge on AUD features in older adults seeking outpatient treatment. Methods: baseline data from the German and Danish ELDERLY-sites (n=544) were used. AUD diagnoses were obtained with the Mini International Neuropsychiatric Interview, alcohol use information with Form 90. Results: Lost control, desired control, mental/physical problem, and craving were the most prevalent (> 70 %) AUD-symptoms. 54.9 % reported severe DSM-5 AUD (moderate: 28.2 %, mild: 16.9 %). Mean daily alcohol use was 6.3 drinks at 12 grams ethanol each. 93.9 % reported binging. More intense alcohol use was associated with greater AUD-severity and male gender. Country effects showed for alcohol use and AUD-severity. Conclusion: European ELDERLY-participants presented typical dependence symptoms, a wide range of severity, and intense alcohol use. This may underline the clinical significance of AUD in treatment-seeking seniors.

Using Machine Learning to Classify Individuals with Alcohol Use Disorder Based on Treatment Seeking Status

2019 ◽  
Author(s):  
Mary R. Lee ◽  
Vignesh Sankar ◽  
Aaron Hammer ◽  
William G. Kennedy ◽  
Jennifer J. Barb ◽  
...  
Keyword(s):  
Machine Learning ◽  
Alcohol Use ◽  
Alcohol Use Disorder ◽  
Treatment Seeking

scholarly journals Inclusion of Cannabis Users in Alcohol Research Samples: Screening In, Screening Out, and Implications

2020 ◽  
Vol 55 (4) ◽  
pp. 416-423
Author(s):  
Alexandra Venegas ◽  
Lindsay R Meredith ◽  
Ziva D Cooper ◽  
Brandon Towns ◽  
Lara A Ray
Keyword(s):  
Alcohol Use ◽  
Binge Drinking ◽  
Tobacco Use ◽  
Alcohol Use Disorder ◽  
Cannabis Use ◽  
Clinical Severity ◽  
Treatment Seeking ◽  
Higher Alcohol ◽  
The Past ◽  
Heavy Drinkers

Abstract Background Alcohol and cannabis are frequently co-used, as 20–50% of those who drink alcohol report co-using cannabis. This study is based on the argument that alcohol researchers should enroll cannabis users in human laboratory studies of alcohol use disorder (AUD) to strengthen generalizability. This study examines how heavy drinking cannabis users differ from non-cannabis using heavy drinkers. Methods In a community sample of non-treatment-seeking heavy drinkers (n = 551, 35% female), cannabis users were identified through: (a) self-reported cannabis use in the past 6 months and (b) positive urine toxicology test for tetrahydrocannabinol (THC). Cannabis users, identified as described previously, were compared with non-cannabis users on demographic and clinical characteristics. Results Those who endorsed cannabis use in the past 6 months reported more binge drinking days. Participants who tested positive for THC had higher Alcohol Use Disorder Identification Test scores and more binge drinking days. Younger age and being a tobacco smoker were associated with an increased likelihood of cannabis use in the past 6 months, whereas male gender and being a tobacco use were associated with a greater likelihood of testing positive for THC. Individuals with cannabis use disorder (CUD) endorsed more depression and anxiety and had higher AUD symptom counts than cannabis users without CUD. Conclusions The inclusion of cannabis users in AUD samples allows for increased clinical severity. Excluding cannabis users from AUD studies may limit representativeness and expend unnecessary study resources. Lastly, tobacco use may explain a large portion of the effects of cannabis use on sample characteristics. Short Summary Alcohol and cannabis are frequently co-used substances. In a sample of non-treatment-seeking heavy drinkers (n = 551, 35% female), cannabis users reported higher alcohol use and higher likelihood of tobacco use than non-cannabis users. Including cannabis users in alcohol research studies will improve representativeness and likely increase clinical severity.

scholarly journals Familial association of abstinent remission from alcohol use disorder in first-degree relatives of alcohol-dependent treatment-seeking probands

Addiction ◽  
2017 ◽  
Vol 112 (11) ◽  
pp. 1909-1917 ◽  
Author(s):  
Vivia V. McCutcheon ◽  
Marc A. Schuckit ◽  
John R. Kramer ◽  
Grace Chan ◽  
Howard J. Edenberg ◽  
...  
Keyword(s):  
Alcohol Use ◽  
Alcohol Use Disorder ◽  
Treatment Seeking ◽  
First Degree Relatives ◽  
Familial Association ◽  
Alcohol Dependent

scholarly journals Melatonin for Treatment-Seeking Alcohol Use Disorder patients with sleeping problems: A randomized clinical pilot trial

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Marie N. S. Gendy ◽  
Dina Lagzdins ◽  
Jessika Schaman ◽  
Bernard Le Foll
Keyword(s):  
Alcohol Use ◽  
Alcohol Use Disorder ◽  
Pilot Trial ◽  
Complex Problem ◽  
Treatment Seeking ◽  
Future Research ◽  
Treatment Change ◽  
Sleeping Problems ◽  
Before And After ◽  
The Difference

Abstract A high percentage of subjects diagnosed with alcohol use disorder (AUD) suffer from sleeping difficulties. Lack of sleep could lead AUD patients to relapse or, sometimes, to suicide. Most of the currently prescribed medications to treat this complex problem retain a high risk of side effects and/or dependence. Therefore, the aim of the current clinical trial is to investigate the possibility of the use of a safer treatment, such as the natural health product melatonin, to treat alcohol-related sleeping problems. Sixty treatment-seeking AUD subjects were assigned to melatonin (5 mg) or placebo for 4 weeks of treatment. Change in sleeping quality which is the primary outcome of the study was assessed using the Pittsburgh sleep quality index (PSQI) scale. Linear mixed models were used to statistically analyze the difference in scores before and after 4 weeks of treatment. There was a reduction in the global PSQI score in both groups with no significant drug effect between groups. In conclusion, the use of melatonin (5 mg)/day didn’t differ from placebo in decreasing sleeping problems in a sample of AUD subjects after 4 weeks of treatment. However, higher doses are worth exploring in future research.

Sign in / Sign up

Export Citation Format

Share Document